Secreted growth differentiation factor15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders

Geriatrics and Gerontology International

Volumn 16, Issue , 2016, Pages 17-29

  Fujita, Yasunori ^a   Taniguchi, Yu ^a   Shinkai, Shoji ^a   Tanaka, Masashi ^a   Ito, Masafumi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Age related disorders; Aging; Biomarker; Growth differentiation factor15; Mitochondrial dysfunction

Indexed keywords

BIOLOGICAL MARKER; GROWTH DIFFERENTIATION FACTOR 15; GDF15 PROTEIN, HUMAN;

AGING; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CELL STRESS; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY YIELD; GENE MUTATION; GENETIC DISORDER; GERIATRIC DISORDER; HUMAN; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL GENE; NONHUMAN; PRIORITY JOURNAL; REVIEW; BLOOD; METABOLISM; MITOCHONDRION;

AGING; BIOMARKERS; CARDIOVASCULAR DISEASES; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MITOCHONDRIA;

EID: 84961647374     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12724     Document Type: Review

References (126)

1. Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 2013; 24: 373-384.
2. Wiklund FE, Bennet AM, Magnusson PK etal. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 2010; 9: 1057-1064.
3. Eggers KM, Kempf T, Wallentin L, Wollert KC, Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013; 59: 1091-1098.
4. Fuchs T, Trollor JN, Crawford J etal. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study. Aging Cell 2013; 12: 882-889.
5. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013; 153: 1194-1217.
6. Lane RK, Hilsabeck T, Rea SL. The role of mitochondrial dysfunction in age-related diseases. Biochim Biophys Acta 2015; 1847: 1387-1400.
7. Fujita Y, Ito M, Kojima T, Yatsuga S, Koga Y, Tanaka M. GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion 2015; 20: 34-42.
8. Yatsuga S, Fujita Y, Ishii A etal. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol 2015; 78: 814-823.
9. Kalko SG, Paco S, Jou C etal. Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics 2014; 15: 91.
10. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1997; 1354: 40-44.
11. Bootcov MR, Bauskin AR, Valenzuela SM etal. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997; 94: 11514-11519.
12. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-908.
13. Lawton LN, Bonaldo MF, Jelenc PC etal. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene 1997; 203: 17-26.
14. Paralkar VM, Vail AL, Grasser WA etal. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998; 273: 13760-13767.
15. Bottner M, Suter-Crazzolara C, Schober A, Unsicker K. Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res 1999; 297: 103-110.
16. Shnaper S, Desbaillets I, Brown DA etal. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer 2009; 125: 2624-2630.
17. Bauskin AR, Jiang L, Luo XW, Wu L, Brown DA, Breit SN. The TGF-beta superfamily cytokine MIC-1/GDF15: secretory mechanisms facilitate creation of latent stromal stores. J Interferon Cytokine Res 2010; 30: 389-397.
18. Bauskin AR, Brown DA, Junankar S etal. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 2005; 65: 2330-2336.
19. Min KW, Liggett JL, Silva G etal. NAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway. Oncogene 2015 (April 20); doi: 10.1038/onc.2015.95; [Epub ahead of print].
20. Li PX, Wong J, Ayed A etal. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000; 275: 20127-20135.
21. Ponnaluri VK, Vadlapatla RK, Vavilala DT, Pal D, Mitra AK, Mukherji M. Hypoxia induced expression of histone lysine demethylases: implications in oxygen-dependent retinal neovascular diseases. Biochem Biophys Res Commun 2011; 415: 373-377.
22. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 2010; 30: 344-353.
23. Albertoni M, Shaw PH, Nozaki M etal. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002; 21: 4212-4219.
24. Akiyama M, Okano K, Fukada Y, Okano T. Macrophage inhibitory cytokine MIC-1 is upregulated by short-wavelength light in cultured normal human dermal fibroblasts. FEBS Lett 2009; 583: 933-937.
25. Baek SJ, Horowitz JM, Eling TE. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 2001; 276: 33384-33392.
26. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005; 67: 356-364.
27. Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004; 279: 6883-6892.
28. Yang H, Park SH, Choi HJ, Moon Y. The integrated stress response-associated signals modulate intestinal tumor cell growth by NSAID-activated gene 1 (NAG-1/MIC-1/PTGF-beta). Carcinogenesis 2010; 31: 703-711.
29. Baek SJ, Kim JS, Jackson FR, Eling TE, McEntee MF, Lee SH. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 2004; 25: 2425-2432.
30. Lee SH, Krisanapun C, Baek SJ. NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 2010; 31: 719-728.
31. Shim M, Eling TE. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem 2005; 280: 18636-18642.
32. Cekanova M, Lee SH, McEntee MF, Baek SJ. MCC-555-induced NAG-1 expression is mediated in part by KLF4. Eur J Pharmacol 2010; 637: 30-37.
33. Tsai VW, Macia L, Johnen H etal. TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PLoS ONE 2013; 8: e55174.
34. Johnen H, Lin S, Kuffner T etal. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007; 13: 1333-1340.
35. Chrysovergis K, Wang X, Kosak J etal. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int J Obes (Lond) 2014; 38: 1555-1564.
36. Xu J, Kimball TR, Lorenz JN etal. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006; 98: 342-350.
37. Kempf T, Eden M, Strelau J etal. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98: 351-360.
38. Kempf T, Zarbock A, Widera C etal. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011; 17: 581-588.
39. Strelau J, Sullivan A, Bottner M etal. Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J Neurosci 2000; 20: 8597-8603.
40. Subramaniam S, Strelau J, Unsicker K. Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways. J Biol Chem 2003; 278: 8904-8912.
41. Strelau J, Strzelczyk A, Rusu P etal. Progressive postnatal motoneuron loss in mice lacking GDF-15. J Neurosci 2009; 29: 13640-13648.
42. Schindowski K, von Bohlen und Halbach O, Strelau J etal. Regulation of GDF-15, a distant TGF-beta superfamily member, in a mouse model of cerebral ischemia. Cell Tissue Res 2011; 343: 399-409.
43. Kim KK, Lee JJ, Yang Y, You KH, Lee JH. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 2008; 29: 704-712.
44. de Jager SC, Bermudez B, Bot I etal. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med 2011; 208: 217-225.
45. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 2015; 116: 4-12.
46. Wilkins HM, Carl SM, Swerdlow RH. Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies. Redox Biol 2014; 2C: 619-631.
47. Tanaka M, Nishigaki Y, Fuku N, Ibi T, Sahashi K, Koga Y. Therapeutic potential of pyruvate therapy for mitochondrial diseases. Mitochondrion 2007; 7: 399-401.
48. Bratic A, Larsson NG. The role of mitochondria in aging. J Clin Invest 2013; 123: 951-957.
49. Short KR, Bigelow ML, Kahl J etal. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A 2005; 102: 5618-5623.
50. Benzi G, Pastoris O, Marzatico F, Villa RF, Dagani F, Curti D. The mitochondrial electron transfer alteration as a factor involved in the brain aging. Neurobiol Aging 1992; 13: 361-368.
51. Lenaz G, Bovina C, Castelluccio C etal. Mitochondrial complex I defects in aging. Mol Cell Biochem 1997; 174: 329-333.
52. Manczak M, Jung Y, Park BS, Partovi D, Reddy PH. Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem 2005; 92: 494-504.
53. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 1992; 2: 324-329.
54. Yen TC, Su JH, King KL, Wei YH. Ageing-associated 5kb deletion in human liver mitochondrial DNA. Biochem Biophys Res Commun 1991; 178: 124-131.
55. Fayet G, Jansson M, Sternberg D etal. Ageing muscle: clonal expansions of mitochondrial DNA point mutations and deletions cause focal impairment of mitochondrial function. Neuromuscul Disord 2002; 12: 484-493.
56. Taylor RW, Barron MJ, Borthwick GM etal. Mitochondrial DNA mutations in human colonic crypt stem cells. J Clin Invest 2003; 112: 1351-1360.
57. Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet 2015; 16: 530-542.
58. Chomyn A, Martinuzzi A, Yoneda M etal. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci U S A 1992; 89: 4221-4225.
59. Hayashi J, Ohta S, Kikuchi A, Takemitsu M, Goto Y, Nonaka I. Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction. Proc Natl Acad Sci U S A 1991; 88: 10614-10618.
60. Larsson NG. Somatic mitochondrial DNA mutations in mammalian aging. Annu Rev Biochem 2010; 79: 683-706.
61. Bender A, Krishnan KJ, Morris CM etal. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-517.
62. Payne BA, Chinnery PF. Mitochondrial dysfunction in aging: much progress but many unresolved questions. Biochim Biophys Acta 2015; 1847: 1347-1353.
63. Bua E, Johnson J, Herbst A etal. Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers. Am J Hum Genet 2006; 79: 469-480.
64. Trifunovic A, Wredenberg A, Falkenberg M etal. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429: 417-423.
65. Tyynismaa H, Mjosund KP, Wanrooij S etal. Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc Natl Acad Sci U S A 2005; 102: 17687-17692.
66. Wang X, Chrysovergis K, Kosak J etal. hNAG-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling. Aging (Albany NY) 2014; 6: 690-704.
67. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 2011; 123: 2101-2110.
68. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-2950.
69. Ritov VB, Menshikova EV, Azuma K etal. Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am J Physiol Endocrinol Metab 2010; 298: E49-E58.
70. Mootha VK, Lindgren CM, Eriksson KF etal. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
71. Patti ME, Butte AJ, Crunkhorn S etal. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003; 100: 8466-8471.
72. Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsoe R, Dela F. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia 2007; 50: 790-796.
73. Turner N, Bruce CR, Beale SM etal. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 2007; 56: 2085-2092.
74. Chanseaume E, Tardy AL, Salles J etal. Chronological approach of diet-induced alterations in muscle mitochondrial functions in rats. Obesity (Silver Spring) 2007; 15: 50-59.
75. Laurent D, Yerby B, Deacon R, Gao J. Diet-induced modulation of mitochondrial activity in rat muscle. Am J Physiol Endocrinol Metab 2007; 293: E1169-E1177.
76. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401-414.
77. Martin SD, McGee SL. The role of mitochondria in the aetiology of insulin resistance and type 2 diabetes. Biochim Biophys Acta 2014; 1840: 1303-1312.
78. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307: 384-387.
79. Koves TR, Ussher JR, Noland RC etal. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7: 45-56.
80. Anderson EJ, Lustig ME, Boyle KE etal. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009; 119: 573-581.
81. Dostalova I, Roubicek T, Bartlova M etal. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 2009; 161: 397-404.
82. Vila G, Riedl M, Anderwald C etal. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 2011; 57: 309-316.
83. Kempf T, Guba-Quint A, Torgerson J etal. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol 2012; 167: 671-678.
84. Carstensen M, Herder C, Brunner EJ etal. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol 2010; 162: 913-917.
85. Twig G, Hyde B, Shirihai OS. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim Biophys Acta 2008; 1777: 1092-1097.
86. Papanicolaou KN, Kikuchi R, Ngoh GA etal. Mitofusins 1 and 2 are essential for postnatal metabolic remodeling in heart. Circ Res 2012; 111: 1012-1026.
87. Ikeda Y, Shirakabe A, Maejima Y etal. Endogenous Drp1 mediates mitochondrial autophagy and protects the heart against energy stress. Circ Res 2015; 116: 264-278.
88. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371: 1800-1809.
89. Diamant M, Lamb HJ, Groeneveld Y etal. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003; 42: 328-335.
90. Scheuermann-Freestone M, Madsen PL, Manners D etal. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003; 107: 3040-3046.
91. Montaigne D, Marechal X, Coisne A etal. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 2014; 130: 554-564.
92. Lind L, Wallentin L, Kempf T etal. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009; 30: 2346-2353.
93. Wollert KC, Kempf T, Peter T etal. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007; 115: 962-971.
94. Eggers KM, Kempf T, Lagerqvist B etal. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 2010; 3: 88-96.
95. Khan SQ, Ng K, Dhillon O etal. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009; 30: 1057-1065.
96. Bonaca MP, Morrow DA, Braunwald E etal. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2011; 31: 203-210.
97. Kempf T, von Haehling S, Peter T etal. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1054-1060.
98. Anand IS, Kempf T, Rector TS etal. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387-1395.
99. Stahrenberg R, Edelmann F, Mende M etal. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010; 12: 1309-1316.
100. Izumiya Y, Hanatani S, Kimura Y etal. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014; 30: 338-344.
101. Aliev G, Palacios HH, Walrafen B, Lipsitt AE, Obrenovich ME, Morales L. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int J Biochem Cell Biol 2009; 41: 1989-2004.
102. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 2000; 21: 455-462.
103. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006; 15: 1437-1449.
104. Xie H, Guan J, Borrelli LA, Xu J, Serrano-Pozo A, Bacskai BJ. Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model. J Neurosci 2013; 33: 17042-17051.
105. Trushina E, Nemutlu E, Zhang S etal. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS ONE 2012; 7: e32737.
106. David DC, Hauptmann S, Scherping I etal. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 2005; 280: 23802-23814.
107. Rhein V, Song X, Wiesner A etal. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A 2009; 106: 20057-20062.
108. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 14670-14675.
109. Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci 2015; 40: 200-210.
110. Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010; 486: 235-239.
111. Chen L, Xie Z, Turkson S, Zhuang X. A53T human alpha-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J Neurosci 2015; 35: 890-905.
112. Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J Cell Biol 2010; 189: 671-679.
113. Kazlauskaite A, Muqit MM. PINK1 and Parkin - mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease. FEBS J 2015; 282: 215-223.
114. Fernandez-Moriano C, Gonzalez-Burgos E, Gomez-Serranillos MP. Mitochondria-targeted protective compounds in Parkinson's and Alzheimer's diseases. Oxid Med Cell Longev 2015; 2015: 408927.
115. Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol 2013; 106-107: 17-32.
116. Mizuno Y, Ohta S, Tanaka M etal. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989; 163: 1450-1455.
117. Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol 1991; 30: 563-571.
118. Ikebe S, Tanaka M, Ohno K etal. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 1990; 170: 1044-1048.
119. Jiang J, Wen W, Brown DA etal. The relationship of serum macrophage inhibitory cytokine-1 levels with gray matter volumes in community-dwelling older individuals. PLoS ONE 2015; 10: e0123399.
120. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
121. Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest 2002; 110: 1383-1388.
122. Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol 2014; 15: 634-646.
123. Loffredo FS, Steinhauser ML, Jay SM etal. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013; 153: 828-839.
124. Sinha M, Jang YC, Oh J etal. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 2014; 344: 649-652.
125. Katsimpardi L, Litterman NK, Schein PA etal. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014; 344: 630-634.
126. Egerman MA, Cadena SM, Gilbert JA etal. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab 2015; 22: 164-174.